题目

NleB, a Bacterial Effector with Glycosyltransferase Activity, Targets GAPDH Function to Inhibit NF-kB Activation

时间：4月19日14:30-17:30

地点：

主讲人： Prof. Philip R. Hardwidge

继教分：记I类继教分2分

简介：

Philip R. Hardwidge, Ph.D.

Associate Professor with tenure, Department of Diagnostic Medicine/Pathobiology

Kansas State University.

Education

B.S., Microbiology, Summa cum laude University of Illinois, Urbana, IL 1993-1997

Ph.D., Biomedical Sciences Mayo Clinic Graduate School, Rochester, MN 1997-2002

Postdoctoral Fellowship, Microbiology/Proteomics University of British Columbia, Vancouver, Canada 2002-2005

Academic and Professional Appointments

Assistant Professor, Biology/Microbiology, South Dakota State University, Brookings, SD 2005-2008

Assistant Professor, Microbiology, University of Kansas Medical Center, Kansas City, KS 2009-2012

Associate Professor (tenured), Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 2012-present

Research Interests

My laboratory is interested in understanding, treating, and preventing diarrheal disease caused by bacterial pathogens. We primarily study several virotypes of Escherichia coli that cause diarrhea and malnutrition in humans and livestock, including E. coli O157:H7, non-O157 STEC, and enterotoxigenic E. coli (ETEC). These pathogens, as well as other enteric bacteria that use contact-dependent secretion systems, represent important threats to food safety, biosecurity, and animal health. In many cases, vaccines are not available or are ineffective, and the basic molecular microbiology of the host-pathogen interaction is relatively poorly understood. Additionally, bacterial virulence proteins utilize molecular mechanisms that are also conserved among viruses of importance to biosecurity. We have discovered several novel molecular mechanisms by which bacterial proteins subvert the host innate immune system to promote bacterial colonization and transmission. We are employing our unique knowledge of these proteins and their mammalian targets to studies of metabolic syndromes and cancer. We are also developing novel proteomic techniques to identify vaccine targets in other organisms.